Rock Springs Capital Management LP

Filings by Rock Springs Capital Management LP span 9 companies, the busiest being Atea Pharmaceuticals, Inc., Inozyme Pharma, Inc. and Theseus Pharmaceuticals, Inc. We count 23 filings; the first trade dates from 15 April 2014 and the latest from 26 October 2021.

Every open-market trade on record is a purchase: 10 purchases worth €38.9M, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2021 to date brings 3 purchases and no sales.

The median purchase comes to €3.5M. On 9 out of 9 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 5 purchases show a median change of +149.4%, with the price up in 80% of them. This is a record of the past, not a forecast.

Most recently, on 26 October 2021, the filings show an open-market purchase worth €6.9M in Xilio Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.